快樂小藥師
本部落格為介紹醫藥相關知識部落格,並沒有販賣藥品。此外文章部分內容可能會引起您的不安或是心理不適,在按下繼續閱讀前,請先自我評估,謝謝(原創文章如需轉載請先告知 左右水平廣告輪播-語法
  • // 如果你希望圖片繼續多一點,那就自己再複製增加

ht_110622_laviv_azficel_t_300x225.png  

The US Food and Drug Administration (FDA) late yesterday approved the first autologous aesthetic cell therapy to improve the appearance of moderate to severe nasolabial fold wrinkles in adults.

The product, azficel-T (laVív), is from Fibrocell Science, Inc, a company focused on developing personalized cell therapies for aesthetic, medical, and scientific applications.

According to the company, creating azficel-T involves a patented technology whereby fibroblasts are extracted from behind the patient's ear and sent to the Fibrocell Science laboratory, where they are multiplied for about 3 months and then frozen until needed.

Over a series of 3 treatment sessions, typically 3 to 6 weeks apart, they are injected into nasolabial folds to reduce the appearance of smile lines.

The company says the therapy will become available gradually through trained clinical investigators in select metropolitan areas. As manufacturing capacity is increased and more physicians trained, the number of cities served will expand as well.

The product will be mostly administered by dermatologists and plastic surgeons; only physicians who complete a Fibrocell-approved training program will be able to administer it.

The training program teaches proper biopsy collection and shipment procedures, treatment preparation and injection technique, and logistics tracking to ensure that the cells received by each patient are derived from that same patient.

"Revolutionary" Approach

"The concept of using a patient's own collagen-making cells is a revolutionary way to help treat nasolabial fold wrinkles and help restore a fresh appearance," Robert A. Weiss, MD, clinical associate professor, Johns Hopkins School of Medicine, Baltimore, and director of the Maryland Laser Skin and Vein Institute, Hunt Valley, noted in a company-issued statement.

"Since this is a biological process that works over time, [azficel-T] is able to provide gradual and natural-looking results," noted Dr. Weiss, who participated in clinical trials of azficel-T.

This approach is "likely appeal to patients who want to take a very new approach to treating wrinkles," Stacy Smith, MD, associate clinical professor in the Division of Dermatology at the University of California–San Diego, who also worked on azficel-T clinical trials, said in a statement.

"By injecting tens of millions of the person's own fibroblasts, patients now have the option to help smooth smile lines by adding cells to replace those that may have been lost through the aging process," he added.

Babak Azizzadeh, MD, FACS, director of the Center for Advanced Facial Plastic Surgery and assistant clinical professor of facial plastic surgery at University of California–Los Angeles, commented, "It's an interesting and novel approach that will generate some excitement among physicians and some patients.

"But at the end of the day," he told Medscape Medical News, "it's going to depend on whether the results are better than with off-the-shelf injectables, such as Juvederm (Allergan), Restylane (HA North American Sales AB), and Sculptra (Sanofi-Aventis), which are the main competition."

Dr. Azizzadeh was not involved in the studies of azficel-T and has not treated any patients with it.

He added that "a limiting factor is that the patients have to have a biopsy and then wait 3 months before they get their injections, and then they have to go through a series of treatments. It's a long process. Physician acceptability, with the length of time involved, may also be an issue."

2 Pivotal Clinical Trials

The FDA approval was based largely on 2 identical phase 3 multicenter, randomized, double-blind, placebo-controlled studies involving 421 patients who underwent 3 treatment sessions approximately 5 weeks apart.

On the basis of investigators' and patients' assessments, a significantly greater proportion of patients demonstrated a positive response to treatment with azficel-T than with placebo, the company notes. The treatment improved the appearance of nasolabial fold wrinkles for the 6 months of patient follow-up after the last treatment. The company said studies are ongoing, looking at how long beyond 6 months after the last treatment the effect may last.

In clinical trials, azficel-T was well tolerated, according to the company. The most common adverse events were mild to moderate injection-site reactions that usually resolved within 1 week. As part of a postmarketing requirement, Fibrocell will set up a registry of approximately 2700 patients to further evaluate the safety of this autologous cell therapy.

螢幕快照 2011-06-24 下午2.22.45.png  

文章標籤
創作者介紹

快樂小藥師 Im pharmacist nichts glücklich

快樂小藥師 發表在 痞客邦 PIXNET 留言(1) 人氣()


留言列表 (1)

發表留言
  • ssagy
  • 真是欣欣向榮的醫學美容科技啊.....^^

您尚未登入,將以訪客身份留言。亦可以上方服務帳號登入留言

請輸入暱稱 ( 最多顯示 6 個中文字元 )

請輸入標題 ( 最多顯示 9 個中文字元 )

請輸入內容 ( 最多 140 個中文字元 )

請輸入左方認證碼:

看不懂,換張圖

請輸入驗證碼